Agenus Inc. (AGEN) is a Lexington, Massachusetts-based immuno-oncology company developing antibody therapies, most notably the botensilimab plus balstilimab ("BOT+BAL") combination being tested in colorectal and other solid tumors. In Thursday's session, the shares were trading at $5.94 shortly before 11 a.m. in New York, a decline of 7.19% from the previous completed session's close of $6.40. The direction is unambiguously negative. No verified company-specific news, filing, or analyst action accompanied the move, and no fundamental development was identified that explains the size of the drop.
No verified news or fundamental catalyst found for the session. The company has not issued a release since its Nov. 5 third-quarter report and its Nov. 2 investor-conference notice, and the most recent analyst action — a price target increase — dates to Nov. 9. The decline is therefore best assessed as technical and flow-driven.
Several data points support that view. The stock had just risen 3.06% on Nov. 18 and traded as high as $6.50 after the bell, recovering from a 6.54% slide on Nov. 16, so a give-back of part of that bounce is consistent with routine digestion in a name that has no scheduled catalyst before ROBBIN's first patient dosing in the first quarter of 2027. The shares also remain 40% below their late-September closing peak of $9.93 and below the 50-day moving average near $7.30, leaving overhead supply from buyers who accumulated during the autumn run.
A structural consideration likely adds pressure at the margin. Agenus funded itself in July 2026 through a private placement of roughly $85 million upfront, paired with Series A warrants struck at $4.02 and Series B warrants struck at $5.03, plus a resale registration covering the pre-funded and warrant shares. With the common stock still above both strike prices, the market must absorb a large potential supply of newly registered shares, which tends to cap rallies and amplify pullbacks after short-term gains.
Turnover has been running well above the calmer pace of the preceding weeks. The stock traded 568,000 shares on Nov. 16, 859,000 on Nov. 17 and 880,000 on Nov. 18, versus the roughly 300,000-to-500,000-share sessions typical of late October, against a three-month average near 0.95 million shares. Volume has therefore been drifting higher during the decline, which is characteristic of distribution rather than a single isolated print.
Technically, the stock is trading above its 200-day moving average, which sits near $5.16, but below both its 50-day average around $7.30 and its 50-day exponential average near $6.96. A break below $6.00 would test the mid-October closing low of $6.04 and the intraday floor at $5.96 set on Nov. 17; the $6.40-to-$6.50 zone now acts as first resistance. The move was not accompanied by any identifiable sector-wide or macro development, and relative to a market capitalisation of roughly $270 million on about 45.2 million reported shares, it reflects sentiment and positioning rather than a change in the fundamental story.
The score runs from 0 to 100, where 0 reflects no meaningful news and a move that is normal for the stock, and 100 reflects transformative news combined with an extreme, rare price move. Agenus registers 11 out of 100.
Verified news strength was minimal: no filing, release, or analyst revision preceded the session's decline, leaving the fundamental catalyst component close to zero. The price move was also unremarkable by this stock's standards. Agenus has averaged an absolute daily change of about 3.87% over the last 60 sessions, and today's 7.19% decline is only about 1.9 times that figure; moves of equal or larger magnitude occurred 11 times in those 60 sessions. Two weak components produce a low score.
Attention now shifts to the company's operational calendar. Agenus has guided to initiation and first patient enrollment in the ROBBIN Phase 3 study of BOT+BAL in neoadjuvant MSS colon cancer in the first quarter of 2027, with 60 patients dosed targeted for the second quarter of that year and an interim pathologic response assessment in the second half. The Series A warrant milestone is tied to that enrollment disclosure, so trial execution carries direct capital-structure consequences. Investors will also watch the pace of BOT+BAL commercialization progress following the first marketing authorizations granted in Armenia, and any further regulatory filings.
The principal risks are financing-related: management has acknowledged substantial doubt about its ability to continue as a going concern absent additional capital, with existing cash and equivalents guided to fund operations through roughly the third quarter of 2027. Delays in trial start-up, weaker-than-expected product revenue, or adverse data would pressure a valuation that already discounts a meaningful probability of Phase 3 success. Analyst consensus remains constructive with a Buy rating and targets far above the current price, which leaves room for sentiment swings in either direction.
Tickeron's Trending AI Robots page is a curated view of the platform's automated trading strategies. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions appear in this section. Bots differ by strategy logic, trading timeframe, performance metrics, and the symbols they trade, so the featured set rotates as market conditions change. Reviewing the trending list is a practical way to see which approaches are working right now.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AGEN saw its Momentum Indicator move below the 0 level on November 12, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 80 similar instances where the indicator turned negative. In 72 of the 80 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for AGEN turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 39 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
The 10-day moving average for AGEN crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AGEN's RSI Indicator exited the oversold zone, 33 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +6.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where AGEN advanced for three days, in 219 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
AGEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. AGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.622) is normal, around the industry mean (3.592). P/E Ratio (2.383) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (1.994) is also within normal values, averaging (442.120).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of technologies to treat cancers and infectious diseases
Industry Biotechnology